![[Valid RSS]](images/valid-rss-rogers.png "Valid RSS")
This is a valid RSS feed.
This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.
<?xml version="1.0" encoding="UTF-8" standalone="yes"?><rss version="2.0"><channel><title>Press Room</title><link>https://www.news.sanofi.us/</link><description>MediaRoom</description><item><title>New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases</title><link>https://www.news.sanofi.us/2024-04-26-New-data-presented-at-ATS-demonstrate-Sanofis-leadership-in-advancing-potential-new-therapies-for-patients-with-immune-mediated-respiratory-diseases</link><description></description><pubDate>Fri, 26 Apr 2024 01:00:00 -0400</pubDate><guid>https://www.news.sanofi.us/2024-04-26-New-data-presented-at-ATS-demonstrate-Sanofis-leadership-in-advancing-potential-new-therapies-for-patients-with-immune-mediated-respiratory-diseases</guid></item><item><title>New data presented at AAD showcase continued commitment to advance treatments for inflammatory dermatologic diseases</title><link>https://www.news.sanofi.us/2024-03-08-New-data-presented-at-AAD-showcase-continued-commitment-to-advance-treatments-for-inflammatory-dermatologic-diseases</link><description></description><pubDate>Fri, 08 Mar 2024 12:00:00 -0500</pubDate><guid>https://www.news.sanofi.us/2024-03-08-New-data-presented-at-AAD-showcase-continued-commitment-to-advance-treatments-for-inflammatory-dermatologic-diseases</guid></item><item><title>Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma </title><link>https://www.news.sanofi.us/2024-02-24-Dupixent-R-continues-scientific-leadership-with-late-breaking-results-showing-reduced-airway-inflammation-and-mucus-plugging-in-adults-with-uncontrolled-moderate-to-severe-asthma</link><description></description><pubDate>Sat, 24 Feb 2024 08:00:00 -0500</pubDate><guid>https://www.news.sanofi.us/2024-02-24-Dupixent-R-continues-scientific-leadership-with-late-breaking-results-showing-reduced-airway-inflammation-and-mucus-plugging-in-adults-with-uncontrolled-moderate-to-severe-asthma</guid></item><item><title>Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation</title><link>https://www.news.sanofi.us/2024-02-23-Dupixent-R-sBLA-accepted-for-FDA-Priority-Review-for-treatment-of-COPD-with-type-2-inflammation</link><description></description><pubDate>Fri, 23 Feb 2024 01:00:00 -0500</pubDate><guid>https://www.news.sanofi.us/2024-02-23-Dupixent-R-sBLA-accepted-for-FDA-Priority-Review-for-treatment-of-COPD-with-type-2-inflammation</guid></item><item><title>New data presented at AAAAI highlight Sanofi’s scientific leadership across inflammatory diseases</title><link>https://www.news.sanofi.us/2024-02-09-New-data-presented-at-AAAAI-highlight-Sanofis-scientific-leadership-across-inflammatory-diseases</link><description></description><pubDate>Fri, 09 Feb 2024 07:50:00 -0500</pubDate><guid>https://www.news.sanofi.us/2024-02-09-New-data-presented-at-AAAAI-highlight-Sanofis-scientific-leadership-across-inflammatory-diseases</guid></item></channel></rss> If you would like to create a banner that links to this page (i.e. this validation result), do the following:
Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):
If you would like to create a text link instead, here is the URL you can use:
